Results demonstrated that the median expression of sortilin in CLL patients was 24.6% (range from 2.2% to 71.5%) in comparison with healthy individuals which was 4.2% (range from 0.03% to 7.4%) (p≤0.0001) (Figure 1B). Here, SORT1 is linked to B-cell chronic lymphocytic leukemia.